Loading…
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-119M | $-104M | $-70M | -22.6% | - | 16.5% |
| 2024 | $0M | $-104M | $-89M | $-73M | -28.7% | - | 24.4% |
| 2023 | $0M | $-83M | $-72M | $-61M | -29.1% | - | 90.1% |
| 2022 | $0M | $-39M | $-38M | $-33M | 49.0% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 38.79 | 83.53 | 104.55 | 119.66 |
| Research And Development | - | 31.02 | 64.57 | 80.78 | 85.86 |
| Selling General And Administration | - | 7.77 | 18.95 | 23.78 | 33.80 |
| Total Expenses | - | 38.79 | 83.53 | 104.55 | 119.66 |
| Operating Income | - | -38.79 | -83.53 | -104.55 | -119.66 |
| Total Operating Income As Reported | - | -38.79 | -83.53 | -104.55 | -119.66 |
| EBITDA | - | -38.58 | -83.23 | -104.24 | -119.40 |
| Normalized EBITDA | - | -38.58 | -83.23 | -105.11 | -119.40 |
| EBIT | - | -38.79 | -83.53 | -104.55 | -119.66 |
| Interest Income | - | 1.13 | 11.97 | 14.89 | 16.01 |
| Net Interest Income | - | 1.13 | 11.97 | 14.89 | 16.01 |
| Other Non Operating Income Expenses | - | - | -0.02 | 0 | -0.05 |
| Other Income Expense | - | - | -0.02 | 0.87 | -0.05 |
| Interest Income Non Operating | - | 1.13 | 11.97 | 14.89 | 16.01 |
| Net Non Operating Interest Income Expense | - | 1.13 | 11.97 | 14.89 | 16.01 |
| Pretax Income | - | -37.66 | -71.58 | -88.79 | -103.69 |
| Tax Provision | - | - | 0 | 0.23 | 0 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0.18 | 0 |
| Net Income Continuous Operations | - | -37.66 | -71.58 | -89.02 | -103.69 |
| Net Income From Continuing And Discontinued Operation | - | -37.66 | -71.58 | -89.02 | -103.69 |
| Net Income From Continuing Operation Net Minority Interest | - | -37.66 | -71.58 | -89.02 | -103.69 |
| Net Income | - | -37.66 | -71.58 | -89.02 | -103.69 |
| Net Income Common Stockholders | - | -37.66 | -71.58 | -89.02 | -103.69 |
| Net Income Including Noncontrolling Interests | - | -37.66 | -71.58 | -89.02 | -103.69 |
| Normalized Income | - | -37.66 | -71.58 | -89.71 | -103.69 |
| Diluted NI Availto Com Stockholders | - | -37.66 | -71.58 | -89.02 | -103.69 |
| Basic Average Shares | 41.10 | 41.10 | 35.55 | 47.07 | - |
| Diluted Average Shares | 41.10 | 41.10 | 35.55 | 47.07 | - |
| Reconciled Depreciation | - | 0.22 | 0.30 | 0.32 | 0.26 |
| Total Unusual Items | - | - | 0 | 0.87 | 0 |
| Total Unusual Items Excluding Goodwill | - | - | 0 | 0.87 | 0 |
| Special Income Charges | - | - | 0 | 0.87 | 0 |
| Restructuring And Mergern Acquisition | - | - | 0 | -0.87 | 0 |
| General And Administrative Expense | - | 7.77 | 18.95 | 23.78 | 33.80 |
| Other Gand A | - | 7.77 | 18.95 | 23.78 | 33.80 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Enliven Therapeutics, Inc.this co. | ELVN | $2.2B | -20.85 | 4.70 | -22.6% | -17.28 |
| Axogen, Inc. | AXGN | $2.3B | - | 17.49 | -12.2% | 4471.19 |
| Immunome, Inc. | IMNM | $2.2B | -10.49 | 3.51 | -33.5% | -7.14 |
| Mineralys Therapeutics, Inc. | MLYS | $2.2B | -14.28 | 3.41 | -23.9% | - |
| BioCryst Pharmaceuticals, Inc. | BCRX | $2.2B |
| - |
| - |
| - |
| - |
| 8.16 |
| -18.07 |
| -221.4% |
| 7.20 |
| Kodiak Sciences Inc. | KOD | $2.1B | - | 13.58 | -146.1% | - |
| Aurinia Pharmaceuticals Inc. | AUPH | $2.1B | 7.33 | 3.62 | 49.4% | 15.22 |
| Clover Health Investments, Corp. | CLOV | $2.1B | -24.56 | 6.81 | -27.7% | - |
| NovoCure Limited | NVCR | $2.1B | - | 6.12 | -40.0% | - |
| Peer Median | - | -10.49 | 4.87 | -30.6% | 11.21 | |